KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523537-26-00

Enrollment

Registered

2026-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.

Brief summary

Number of participants receiving opnurasib as single agent or in combination with other study treatments and duration of exposure

Detailed description

Safety and tolerability: • Frequency and severity/grade of adverse events (AEs) • Dose interruptions, reductions, and discontinuations

Interventions

DRUGTNO155

DRUGErbitux 5 mg/mL solution for infusion

DRUGJDQ443

DRUGVDT482

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants receiving opnurasib as single agent or in combination with other study treatments and duration of exposure	—

Secondary

Measure	Time frame
Safety and tolerability: • Frequency and severity/grade of adverse events (AEs) • Dose interruptions, reductions, and discontinuations	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 11, 2026